BioCentury
ARTICLE | Clinical News

AKB-4924: Phase Ia started

October 17, 2016 7:00 AM UTC

Aerpio began a double-blind, placebo-controlled, Canadian Phase Ia trial to evaluate single doses of 20, 60, 120, 240, 360 and 480 mg oral AKB-4924 in up to 48 healthy male volunteers. ...